Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | USP7 | Q93009 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10232975 | 0.85 | NAMPT (0.44) | DRD2NAMPTKMT2AWDR5 | |
| SCHEMBL4487502 | 0.83 | KMT2A (0.58) | DRD2NAMPTKMT2ASMN1; SMN2GAA | |
| SCHEMBL1829911 | 0.82 | TSHR (0.59) | TSHRNAMPTSMN1; SMN2GAA | |
| SCHEMBL38654966 | 0.80 | DDB1 (0.54) | TSHRNAMPTSMN1; SMN2USP7GAA | |
| SCHEMBL994653 | 0.79 | NPC1 (0.58) | NPC1RAB9AKMT2AMITFSMN1; SMN2 | |
| SCHEMBL1828113 | 0.77 | TSHR (0.56) | TSHRNAMPTKMT2ASMN1; SMN2GAA | |
| SCHEMBL508353 | 0.77 | TSHR (0.56) | TSHRNAMPTSMN1; SMN2GAA | |
| SCHEMBL964473 | 0.77 | TSHR (0.56) | TSHRNAMPTSMN1; SMN2GAA | |
| SCHEMBL29726432 | 0.77 | TSHR (0.56) | TSHRNAMPTSMN1; SMN2GAA | |
| SCHEMBL27403101 | 0.76 | DYRK1A (0.47) | NAMPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601751-B2 | Indole acetic acid acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070049589-A1 | Indole acetic acid acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049589-A1 | Indole acetic acid acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | TSHR 2547/4885DRD2 1031/4885NAMPT 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.